Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2025 May 20:16:379-381.
doi: 10.18632/oncotarget.28728.

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression

María Laura Polo  1 , Marina Riggio  1 , María May  1 , María Jimena Rodríguez  1 , María Cecilia Perrone  1 , Melody Stallings-Mann  2 , Diego Kaen  3 , Marlene Frost  4 , Matthew Goetz  4 , Judy Boughey  5 , Claudia Lanari  1 , Derek Radisky  2 , Virginia Novaro  1
Affiliations
Published Erratum

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression

María Laura Polo et al. Oncotarget. .
No abstract available

PubMed Disclaimer

Figures

Figure 4
Figure 4. Inhibition of PI3K/Akt/mTOR pathway interferes with the stromal reaction induced by endocrine therapy in C4-HD tumors.
C4-HD tumors were treated for 48 h with MFP, WORT or the combination. (A) Left: MFP-treated tumors showed smaller size compared to WORT or MFP+WORT-treated tumors. Right: H&E staining reveals greater tissue remodeling in MFP-treated tumors. (B) Top: IHC for pS6 shows that WORT inhibited MFP-induced levels. Bottom: WB revealing total and pS6, and ERK1/2. (C) IHC shows that after 12 h of treatment, WORT reduced Ki67 and induced caspase 3 to a lesser extent than MFP. (D) IHC for αSMA and IF for CD31 and F480, show that MFP, but not WORT, affected stromal area, number of CD31 foci and macrophages infiltration. (E) Left: C4-HD tumor sizes after 6 days of treatment with WORT or RAPA (5 mg/kg/day). Combination with WORT or RAPA significantly impaired MFP-induced regression. Right: Representative photographs of treated tumors. Bar: 100 μm.
Figure 6
Figure 6. Tumor cell level of PI3K/Akt pathway determines response to therapy.
(A) WB from cellular extracts revealing PI3K, Akt, total and pS6, and ERK1/2. Akt antibody detected both the endogenous and the myristoylated deleted myrAkt1variant. MCF-7 cells were used as a control. (B) IBH-6-Acl4 and IBH-6-myrAkt1 cells were treated with ICI 1 μM, RAPA 0.1 μM or the combination for 6 days, and final cell number was counted. (C, D) T47D-Acl4 and T47D-myrAkt1 cells were injected into NOD/SCID mice. Tumors of 30 mm2 were treated with MFP, RAPA (5 mg/kg/day) or the combination, and continued for 6 days. Top, left: Tumor sizes expressed as % of pretreatment size. T47D-Acl4 tumors responded mainly to MFP whereas T47D-myrAkt1 tumors responded mainly to RAPA. Representative photographs (right) and H&E (center) of control and treated tumors. Inserts: T47D-Acl4 tumors show MFP-induced blood vessels. Bottom: IHC for pS6 shows that stromal levels were higher in T47D-Acl4 than in T47D-myrAkt1 tumors after MFP treatment. Bar: 50 μm.
See this image and copyright information in PMC

Erratum for

References

Publication types

LinkOut - more resources